Theriva Biologics, Inc. Cash Flow Statement
TOVX|1 years of annual SEC 10-K data (FY2011-FY2011)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid. All figures from audited SEC 10-K filings.
Theriva Biologics, Inc. used $1M in operating cash flow and negative free cash flow of $1M in FY2011.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.80 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2011 |
|---|---|
| Net Income | -$1.7M |
| Depreciation & Amortization | $346.0K |
| Operating Cash Flow | -$1.1M |
| Capital Expenditures | $12.0K |
| Free Cash Flow | -$1.2M |
| FCF Margin | -44.3% |